|Articles|June 11, 2020
Episode 58: Understanding FDA’s Gene Therapy Guidelines
Author(s)Elaine Quilici
Dr. Jonathan Gertler, CEO of Back Bay Life Science Advisors, and Dr. Stephan Gauldie, Senior Vice President of Back Bay, talk about the new guidelines set forth by FDA in regard to gene therapy, and what those new parameters mean for pharma and biotech.
Advertisement
Dr. Jonathan Gertler, CEO of Back Bay Life Science Advisors, and Dr. Stephan Gauldie, Managing Director of Back Bay, talk about the new guidelines set forth by FDA in regard to gene therapy, and what those new parameters mean for pharma and biotech.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Pannel Votes to Loosen Restrictions for Four Peptides
2
Where the True Bottlenecks Exist at FDA for Clinical Trials
3
argenx Acquires Forte Biosciences for $2.2 Billion
4
Moving From Symptom Management to Disease Modification in Parkinson’s Research: Q&A with Dr. Jan Stoehr
5